 | | Abacavir (Ziagen) |  | | Published
January 23, 2001; Updated
February 2013 | Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-01-06 | | | Selected References | | 16. | Severe Hypersensitivity Reactions following Reintroduction with ZIAGEN (abacavir sulfate) Products. FDA MedWatch letter, Glaxo Wellcome, updated 7/27/2000. | |
| 17. | Loeliger
AE, Steel
H, McGuirk
S, Powell
WS, Hetherington
SV.
The abacavir hypersensitivity reaction and interruptions in therapy. AIDS. 2001 Jul;15(10):1325-6
[PubMed ID: 11426085]
| | | No abstract | |
| 18. | Berenguer
J, Padilla
B, Estrada
V, Martín
C, Domingo
P, Kindelán
JM, Ruiz-Guiardin
JM.
Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug. AIDS. 2002 Jun;16(9):1299-301
[PubMed ID: 12045501]
| | | No abstract | |
|
|
|
